PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with 20 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH/MASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
High success rate customer satisfaction in 2022: 97.5%
When is your turn?
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex to present its obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, Nov. 27-29, 2023
Physiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, USA, Nov. 27-29, 2023. This unique...
Physiogenex to present its novel obese hamster model of MetALD at the AASLD Liver Meeting 2023 in Boston, Nov. 10-14
Physiogenex will be presenting a novel obese NASH hamster model of MetALD (Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and...
Physiogenex is a proud sponsor of the Hanson Wade 7th IPF Summit to be held in Boston, Sept. 19-21, 2023: On Sept.20th, Dr. François Briand, our Director of...